Synlogic_Logo_Blue.png
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
September 06, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
Synlogic_Logo_Blue.png
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
August 23, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic_Logo_Blue.png
Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 06:58 ET | Synlogic, Inc.
– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – $106.8 million in cash, cash equivalents and...
Synlogic_Logo_Blue.png
Synlogic Announces Second Quarter 2022 Conference Call and Webcast
July 28, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic_Logo_Blue.png
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
July 12, 2022 07:00 ET | Synlogic, Inc.
Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...
Synlogic_Logo_Blue.png
Synlogic Announces Appointment of General Counsel and Corporate Secretary
June 29, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic_Logo_Blue.png
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
June 21, 2022 07:00 ET | Synlogic, Inc.
BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic_Logo_Blue.png
Synlogic Reminds Stockholders of 2022 Annual General Meeting Details
June 01, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic_Logo_Blue.png
Synlogic Announces First Quarter 2022 Conference Call and Webcast
May 05, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic_Logo_Blue.png
Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium
April 28, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...